Biohaven

Biohaven EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Biohaven (BHVN) as of Oct 28, 2026 is -2.11. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -1.31 — a change of 60.75% (lower).

EV/EBITDA

-2.11

YoY

60.75%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Biohaven is 2025 -2.11 . EV/EBITDA (Enterprise Value to EBITDA) of Biohaven was 2024 -1.31 . It decreases by 60.75% lower compared to the previous year.

The Biohaven EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-6.69 USD
Jan 1, 2019
-3.30 USD
Jan 1, 2020
-13.96 USD
Jan 1, 2021
-7.37 USD
Jan 1, 2022
-2.08 USD
Jan 1, 2023
-2.91 USD
Jan 1, 2024
-1.31 USD
Jan 1, 2025
-2.11 USD
The Biohaven EV/EBITDA history
YEAREV/EBITDAYoY
-2.11+60.75%
-1.31-54.78%
-2.91+39.43%
-2.08-71.70%
-7.37-47.24%
-13.96+323.27%
-3.30-50.71%
-6.69-75.42%
-27.22-83.98%
-169.88-84.74%
-1,113.20—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

EV/EBITDA (Enterprise Value to EBITDA) of Biohaven is -2.11 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Biohaven changed from -1.31 to -2.11, representing a 60.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Biohaven since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Biohaven with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biohaven

All Key Metrics — Biohaven